As PARPs have been defined as therapeutic targets for cancers, metabolic, inflammatory, and neurological diseases, PARP PET tracers allow direct measurement of PARP expression in patients to enhance patient stratification, quantify target engagement by PARP inhibitors, and monitor treatments. This evidence concerns the gene PARP1 and cancer.